Engineered extracellular vesicles show promise in targeting cancer cells and immunosuppressive stromal cells, offering a ...

Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch ...

新京报讯 ...

在该研究中，陆佩华院长带领团队创新性地采用基于纳米抗体的CD7 CAR-T治疗急性髓系白血病，研究结果不仅在肿瘤杀伤力和安全性上取得了显著进展，更为难治复发急性髓系白血病的治疗开辟了新路径。

NDAQ:CRBU) Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 ...

VIR-5818 is under clinical development by Vir Biotechnology and currently in Phase II for Metastatic Colorectal Cancer.

For applications requiring the bivalent antigen binding and an Fc part for detection, phage display generated single chain Fv (scFv) antibody fragments can rapidly be genetically fused to the Fc ...

CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving ...